Strategic Signals Weekly

Scholar Rock Holding Corporation has resubmitted its Biologics License Application (BLA) for apitegromab, targeting spinal muscular atrophy (SMA) in children and adults. The company anticipates FDA acceptance within 30 days, with a Prescription Drug User Fee Act (PDUFA) action date expected in late September 2026.

Drug: apitegromab · Indication: spinal muscular atrophy

Ultragenyx Pharmaceutical Inc. announced that the FDA has accepted for review its resubmitted Biologics License Application (BLA) for UX111 (rebisufligene etisparvovec) AAV9 gene therapy. The BLA seeks accelerated approval for the treatment of Sanfilippo syndrome Type A (MPS IIIA). The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of September 19, 2026.

Drug: UX111 (rebisufligene etisparvovec) · Indication: Sanfilippo syndrome Type A (MPS IIIA)

BioXcel Therapeutics announced on April 1, 2026, that the FDA accepted its supplemental New Drug Application for IGALMI. The sNDA seeks approval for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting. The FDA has set a PDUFA target action date of November 14, 2026.

Drug: IGALMI · Indication: acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting

Scholar Rock Holding Corporation has resubmitted its Biologics License Application (BLA) for apitegromab, targeting spinal muscular atrophy (SMA) in children and adults. The company anticipates FDA acceptance within 30 days, with a Prescription Drug User Fee Act (PDUFA) action date expected in late September 2026.

Drug: apitegromab · Indication: spinal muscular atrophy

IO Biotech, Inc. ceased operations and filed for Chapter 7 bankruptcy on March 31, 2026, following a review of strategic alternatives. This action will result in the liquidation of the company's assets, the appointment of a Chapter 7 trustee, and the termination of all employees and the board of directors. It is highly unlikely that common stock holders will receive any payment from the bankruptcy proceedings.

Ensysce Biosciences Inc. is exploring strategic alternatives for its business. To maintain enterprise value during this period, the company approved retention packages for three managers and its Chief Financial Officer, totaling approximately $205,475. Board member Lee Rauch resigned, citing disagreement with these compensation packages and prior board actions.

Esperion Therapeutics, Inc. secured an additional $25 million in term loans and completed the acquisition of Corstasis Therapeutics Inc. for an upfront cash consideration of $75 million, plus potential future milestones. Concurrently, the company entered into a Royalty Purchase Agreement with Athyrium Opportunities IV Acquisition LP, selling a portion of its future royalties and milestones from Bempedoic Acid and other licensed products in the Otsuka Territory for $50 million.

Drug: Bempedoic Acid · Partner: Athyrium Opportunities IV Acquisition LP

SCYNEXIS, Inc. entered into an asset purchase agreement with Poxel SA to acquire Poxel's direct AMP kinase activator research and development program assets, including the compound PXL-770. SCYNEXIS will make an upfront payment of $8 million to Poxel, with potential milestone payments totaling up to $188 million for development and commercial achievements, including initiation of Phase 2 and Phase 3 clinical trials and sales targets.

Drug: PXL-770 · Partner: Poxel SA

Kezar Life Sciences, Inc. has entered into a definitive merger agreement with Aurinia Pharma U.S., Inc. and its parent, Aurinia Pharmaceuticals Inc. Aurinia will launch a cash tender offer to acquire all outstanding Kezar shares for $6.955 per share plus one contingent value right (CVR) per share. The transaction, which is subject to customary closing conditions including a minimum tender of 50% of shares, is expected to close in the second quarter of 2026.

Partner: Aurinia Pharma U.S., Inc. and Aurinia Pharmaceuticals Inc.

Entera Bio Ltd. completed a private placement with funds affiliated with BVF Partners LP, raising approximately $10.0 million. The financing involved the issuance of units comprising ordinary shares (or pre-funded warrants) and ordinary share warrants. The company plans to use the net proceeds to fund the initiation of its Phase 3 registrational study for EB613 in postmenopausal women with osteoporosis, alongside general working capital and corporate purposes.

InspireMD, Inc. entered into an Equity Distribution Agreement with BTIG, LLC to establish a new "at-the-market" offering program. This program allows the company to sell up to $75,000,000 of its common stock from time to time. Proceeds are intended for general corporate purposes, including research and development, sales and marketing, and working capital. Concurrently, the company terminated its previous ATM agreement with Piper Sandler & Co.

Celldex Therapeutics, Inc. entered into an underwriting agreement for a public offering of 10,345,000 shares of its common stock at $29.00 per share. The offering is expected to generate approximately $282 million in net proceeds for the company. The underwriters also have a 30-day option to purchase up to an additional 1,551,750 shares.

Aytu BioPharma amended warrants issued to institutional investors in 2023 and 2025 to resolve an accounting ambiguity. The original language regarding beneficial ownership blockers caused the warrants to be classified as liabilities, resulting in recorded liabilities of $18.1 million and $25.2 million in Q1 and Q2 2026, respectively. The amendment clarifies the blockers to ensure equity classification going forward, which is expected to reduce warrant liability and increase equity value.

BiomX Inc. entered into an Option and Undertaking Agreement with Mandragola Ltd. to acquire DR. Frucht Systems Ltd. (DFSL), a developer of LADAR-based detection systems for security and defense applications. The acquisition consideration includes a $0.1 million cash payment, a $5 million convertible promissory note, and various equity instruments, with additional contingent payments based on DFSL's future revenues. This strategic move, contingent on Mandragola's prior acquisition of DFSL shares and Israel Innovation Authority approval, will make DFSL a majority-owned operating subsidiary of BiomX.